Interestingly, the phosphodiesterase IV (PDE4D) inhibitor roflumilast has been reported to ameliorate the symptoms of T2DM and insulin resistance by potentiating cAMP signaling, possibly influencing insulin secretion [83]. The gene discussed is PDE4D; the disease is type 2 diabetes mellitus.